ArticleEpidemiology (Cambridge, Mass.)2020
Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons.
Abstract readComment
In one paragraph
Article in Epidemiology (Cambridge, Mass.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial.BMC pharmacology & toxicology · 2024Trial
- Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Trial
- An Anti-HIV Drug Is Highly Effective Against SARS-CoV-2 In Vitro and Has Potential Benefit for Long COVID Treatment.Viruses · 2025Article
- BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.Journal of medical virology · 2024Article
- Clinical Outcomes of Coronavirus Disease 2019 in People Living With Human Immunodeficiency Virus in South Korea: A Nationwide Population-Based Cohort Study.Influenza and other respiratory viruses · 2024Article
- Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B.BMC infectious diseases · 2023Article
- Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV.Viruses · 2023Observational
- Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19.Annals of internal medicine · 2023Review
- The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital.BMC infectious diseases · 2023Observational
- Observational
- SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.AIDS (London, England) · 2022Review
- Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data.Infectious diseases and therapy · 2022Article
- Observational
- Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial.EClinicalMedicine · 2021Article
- Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH).Expert opinion on pharmacotherapy · 2021Article
- Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients.Frontiers in oncology · 2021Review
Corrections and comments
- Comment on
Authors and funding
8 authors.
Julia Del AmoNational Plan against AIDS, Ministry of Health, Paseo del Prado 19, 28004 Madrid, Spain. jamo@mscbs.es.
Rosa PoloNational Plan on AIDS, Ministry of Health, Madrid, Spain.
Santiago MorenoUniversity Hospital Ramón y Cajal and HIV, Network of Excellence, Madrid, Spain.
Asunción DíazNational Plan on AIDS, Ministry of Health, University Hospital Ramón y Cajal, and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Esteban MartínezHIV Network of Excellence, Madrid, and University Hospital Clinic, Barcelona, Spain.
José Ramón ArribasHIV Network of Excellence and University Hospital La Paz, IdiPAZ, Madrid, Spain.
Inma JarrínHIV Network of Excellence and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Miguel A HernánDepartments of Epidemiology and Biostatistics, Harvard School T.H. Chan of Public Health, Boston, MA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA.
Funding
Dynamic Strategies for the clinical management of HIV diseaseR37AI102634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MIGUEL HERNAN · 2018 to 2026
$5.3MNIAID NIH HHS R37 AI102634
Abstract
PubMed holds no abstract for this paper.
Indexed as
Coronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusClinical Laboratory TechniquesCohort StudiesCOVID-19COVID-19 TestingHIV InfectionsHospitalizationHumansIncidenceSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.